CSIMarket
 
Astria Therapeutics inc   (ATXS)
Other Ticker:  
 
 
Price: $9.0500 $0.03 0.333%
Day's High: $9.2 Week Perf: -1.63 %
Day's Low: $ 8.85 30 Day Perf: 0.56 %
Volume (M): 492 52 Wk High: $ 16.90
Volume (M$): $ 4,451 52 Wk Avg: $9.14
Open: $9.02 52 Wk Low: $4.26



 Market Capitalization (Millions $) 473
 Shares Outstanding (Millions) 52
 Employees 10
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -82
 Cash Flow (TTM) (Millions $) -30
 Capital Exp. (TTM) (Millions $) 0

Astria Therapeutics Inc
Astria Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing drugs for the treatment of cancer and other diseases. The company was founded in 2018 and is headquartered in San Francisco, California.

Astria Therapeutics has developed an innovative platform technology that enables the company to develop targeted therapies that can selectively kill cancer cells while sparing healthy cells. The company's technology uses a proprietary approach to deliver cancer treatments directly to tumor cells, which can potentially reduce the side effects associated with traditional chemotherapy and radiation therapy.

The company's lead drug candidate, AST-008, is being developed for the treatment of solid tumors. AST-008 is a small molecule inhibitor that targets a specific protein known as CDC7, which is involved in the regulation of DNA replication. By targeting CDC7, AST-008 can prevent cancer cells from dividing and multiplying, which can ultimately lead to their death.

Astria Therapeutics has also developed a pipeline of other drug candidates that are being developed for the treatment of various types of cancer, including breast cancer, lung cancer, and pancreatic cancer. The company's pipeline includes both small molecule inhibitors and antibody-drug conjugates (ADCs), which are designed to selectively deliver drugs to cancer cells.

In addition to its cancer drug development programs, Astria Therapeutics is also developing drugs for the treatment of inflammatory and autoimmune diseases. The company's lead drug candidate for these indications is a small molecule inhibitor of a protein called CCR5, which is involved in the immune response.

Astria Therapeutics has received funding from several leading venture capital firms, including F-Prime Capital, Boxer Capital, and Novo Holdings. The company's management team includes experienced executives with years of experience in the biopharmaceutical industry, including CEO Weidong Zhong, who previously served as the Chief Scientific Officer of Tesaro, Inc., a pharmaceutical company that was acquired by GlaxoSmithKline in 2018.


   Company Address: 75 State Street Suite 1400 Boston 2109 MA
   Company Phone Number: 349-1971   Stock Exchange / Ticker: NASDAQ ATXS
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Business Update

Astria Therapeutics Presents Promising Findings and Updates on Therapies for Allergic and Immunological Diseases at EAACI Congress

Published Thu, May 23 2024 12:47 PM UTC

CSIMarket.com is proud to present an article discussing the recent developments and updates from Astria Therapeutics, a leading biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases. This article summarizes two significant announcements made by Astria Therapeutics, including its participation in the European Academy...

Astria Therapeutics Inc

2. Rising Operating Deficit Raises Concerns for Astria Therapeutics Inc. 3. Promising Developments in Drug Pipeline Offer Hope for Astria Therapeutics Inc.

The financial results of Astria Therapeutics Inc (NASDAQ: ATXS) for the first quarter of 2024 reveal a concerning trend of widening operating deficit. The operating deficit for this quarter was reported at $-24.15 million, significantly higher than the deficit of $-13.493 million in the same period of 2023. Furthermore, the net deficit has also increased from $-11.188 million in the first quarter of the prior year to $-19.928 million in the current quarter. These figures signify a deterioration in the financial performance of the company.
On the other hand, Astria Therapeutics Inc has shown promise with the development of STAR-0215, a potential preventative therapy for Hereditary Angioedema (HAE). The company's CEO, Jill C. Milne, has expressed optimism about the prospects of STAR-0215 becoming the preferred choice for HAE treatment. Additionally, the preclinical profile of STAR-0310, a novel therapeutic candidate for allergic and immunological dermatological diseases, was presented at the Society for Investigative Dermatology Annual Meeting. Dr. Chunxia Lily Zhao, Director of Antibody Discovery at Astria Therapeutics, discussed the therapeutic benefits and mechanism of action of STAR-0310, highlighting its potential to address the unmet medical needs in this area.

Business Update

Preclinical Evaluation of STAR-0310: A Promising Therapy for Allergic and Immunological Dermatological Conditions

Published Wed, May 8 2024 12:47 PM UTC

Abstract:This article provides a comprehensive overview of the preclinical profile of STAR-0310, a novel therapeutic candidate developed by Astria Therapeutics for the treatment of allergic and immunological dermatological diseases. The preclinical data was presented at the Society for Investigative Dermatology Annual Meeting, highlighting the potential of STAR-0310 in trans...

Product Service News

Advances in the Development of Monoclonal Antibody Inhibitors for Hereditary Angioedema: A Promising Case Study of Astria Therapeutics' STAR-0215

Published Mon, Mar 25 2024 11:30 AM UTC

Abstract:This article provides an in-depth analysis of the positive initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 clinical trial evaluating STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. The study, conducted by Astria Therapeutics, Inc., a biopharmaceutical company dedicated to developing innovative...

Astria Therapeutics Inc

2 CEO Jill C. Milne's Optimism and Commitment to Innovation Drive Astria Therapeutics Inc. Forward

The recent financial results of Astria Therapeutics Inc, a key player in the Major Pharmaceutical Preparations industry, have been a topic of interest among investors and industry experts alike. Despite reporting a net deficit and operating shortfall for the financial period ending December 31, 2023, the company remains optimistic about its future prospects. With a focus on developing groundbreaking therapies for allergic and immunological diseases, Astria Therapeutics has shown resilience and determination in a challenging market environment.
CEO Jill C. Milne's confidence in STAR-0215 as a potential game-changing preventative therapy for Hereditary Angioedema (HAE) is not to be underestimated. The company's commitment to innovation and patient care is evident in their financial performance and corporate updates, further solidifying their position as a leader in the biopharmaceutical industry.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com